Synthetic lethal kinases in Ras/p53 mutant squamous cell carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Ras and p53 are frequently co-mutated in human cancers, driving increased malignancy.
• These co-mutations create a need for novel therapeutic strategies targeting specific cancer vulnerabilities.

Purpose of the Study:

• To identify druggable targets in squamous cell carcinoma (SCC) with co-existing Ras and p53 pathway mutations.
• To explore the functional kinomic landscape of Ras/p53 mutant SCCs.

Main Methods:

• Utilized arrayed, kinome-focused siRNA screening and oncology drug phenotypic screening.
• Employed syngeneic Ras mutant SCC cell lines with co-mutations in p53 pathway genes (Trp53, p19Arf, Atm, Prkdc).

Main Results:

• Convergent screening implicated phosphoinositol kinases, receptor tyrosine kinases, MAP kinases, cell cycle, and DNA damage response genes as targetable dependencies.
• Observed rewiring of survival pathways in Ras mutant tumors due to co-mutations.
• Identified Nek4 kinase as a candidate therapeutic target.

Conclusions:

• Ras/p53 co-mutations create specific vulnerabilities in SCC.
• Functional kinome profiling reveals targetable dependencies and pathway rewiring.
• Nek4 kinase and other identified targets warrant further investigation for SCC treatment.